BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15310147)

  • 21. A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.
    Guérin M; Thariat J; Ouali M; Bouvier C; Decouvelaere AV; Cassagnau E; Aubert S; Lepreux S; Coindre JM; Valmary-Degano S; Larousserie F; Meilleroux J; Projetti F; Stock N; Galant C; Marie B; Peyrottes I; de Pinieux G; Gomez-Brouchet A
    Hum Pathol; 2016 Apr; 50():70-8. PubMed ID: 26997440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas.
    Salinas-Souza C; De Andrea C; Bihl M; Kovac M; Pillay N; Forshew T; Gutteridge A; Ye H; Amary MF; Tirabosco R; Toledo SR; Baumhoer D; Flanagan AM
    Mod Pathol; 2015 Oct; 28(10):1336-42. PubMed ID: 26248895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma.
    Ragazzini P; Gamberi G; Benassi MS; Orlando C; Sestini R; Ferrari C; Molendini L; Sollazzo MR; Merli M; Magagnoli G; Bertoni F; Bohling T; Pazzagli M; Picci P
    Cancer Detect Prev; 1999; 23(2):129-36. PubMed ID: 10101594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
    Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
    Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 gene amplification in metastatic osteosarcoma.
    Ladanyi M; Cha C; Lewis R; Jhanwar SC; Huvos AG; Healey JH
    Cancer Res; 1993 Jan; 53(1):16-8. PubMed ID: 8416741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
    Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
    Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative genomic hybridization of low-grade central osteosarcoma.
    Tarkkanen M; Böhling T; Gamberi G; Ragazzini P; Benassi MS; Kivioja A; Kallio P; Elomaa I; Picci P; Knuutila S
    Mod Pathol; 1998 May; 11(5):421-6. PubMed ID: 9619593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.
    Overholtzer M; Rao PH; Favis R; Lu XY; Elowitz MB; Barany F; Ladanyi M; Gorlick R; Levine AJ
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11547-52. PubMed ID: 12972634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes.
    Duhamel LA; Ye H; Halai D; Idowu BD; Presneau N; Tirabosco R; Flanagan AM
    Histopathology; 2012 Jan; 60(2):357-9. PubMed ID: 22074548
    [No Abstract]   [Full Text] [Related]  

  • 32. Osteosarcoma in blood relatives.
    Longhi A; Benassi MS; Molendini L; Macchiagodena M; Picci P; Bacci G
    Oncol Rep; 2001; 8(1):131-6. PubMed ID: 11115584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDM2 and CDK4 expression in periosteal osteosarcoma.
    Righi A; Gambarotti M; Benini S; Gamberi G; Cocchi S; Picci P; Bertoni F
    Hum Pathol; 2015 Apr; 46(4):549-53. PubMed ID: 25680902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
    Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
    Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
    Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2.
    Tachibana M; Kawamata H; Fujimori T; Omotehara F; Horiuchi H; Ohkura Y; Igarashi S; Kotake K; Kubota K
    Int J Oncol; 2004 Oct; 25(4):913-20. PubMed ID: 15375540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma.
    Reid AH; Tsai MM; Venzon DJ; Wright CF; Lack EE; O'Leary TJ
    Diagn Mol Pathol; 1996 Mar; 5(1):65-73. PubMed ID: 8919547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.